Therapeutic Asset Ratings
13,155 results matching 1 filter
91,564 assets · 7,904 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cabozantinib
Urethra Cancer
National Cancer Institute (NCI)
P2
B
(60)
Cabozantinib
MIT Family Translocation Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
P2
B
(60)
Cabozantinib
Urothelial Carcinoma
National Cancer Institute (NCI)
P2
B
(60)
Capecitabine
Esophageal Squamous Cell Carcinoma
Chongqing University Cancer Hospital
P2
B
(60)
Capivasertib
Endometrial Carcinoma
M.D. Anderson Cancer Center
P2
B
(60)
Capivasertib
Lymphoma
University of Chicago
P2
B
(60)
Capivasertib
Endometrium Adenocarcinoma
National Cancer Institute (NCI)
P2
B
(60)
Capivasertib
Uterine Corpus Cancer
M.D. Anderson Cancer Center
P2
B
(60)
Carboplatin
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
OHSU Knight Cancer Institute
P2
B
(60)
Carboplatin
Childhood Acute Myeloid Leukemia
Joanna Yi
P2
B
(60)
Carboplatin
Endometrioid Adenocarcinoma
National Cancer Institute (NCI)
P2
B
(60)
Carboplatin
Essential Thrombocythemia
National Cancer Institute (NCI)
P2
B
(60)
Carboplatin
Pancreatic Adenocarcinoma
Seagen, a wholly owned subsidiary of Pfizer
P2
B
(60)
Carboplatin
Pancreatic Endocrine Carcinoma
ECOG-ACRIN Cancer Research Group
P2
B
(60)
Carboplatin
Acquired Polycythemia Vera
National Cancer Institute (NCI)
P2
B
(60)
Carboplatin
SMARCA4-Deficient Sarcoma Of Thorax
Zhijie Wang
P2
B
(60)
Catequentinib
Acral Lentiginous Melanoma
Qilu Hospital of Shandong University
P2
B
(60)
cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine
Her2-Receptor Negative Breast Cancer
University of Washington
P2
B
(60)
CD47/SIRPA-BLOCKING AGENT ALX148
Breast Cancer
ALX Oncology Inc.
P2
B
(60)
Ceralasertib
Breast Carcinoma
National Cancer Institute (NCI)
P2
B
(60)
Ceralasertib
Endometrial Carcinoma
National Cancer Institute (NCI)
P2
B
(60)
Ceralasertib
Breast Cancer
National Cancer Institute (NCI)
P2
B
(60)
Cetrelimab
Prostate Cancer
Janssen Research & Development, LLC
P2
B
(60)
Cetuximab
Brain Neoplasm
Northwell Health
P2
B
(60)
Cetuximab
Malignant Colon Neoplasm
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
P2
B
(60)
Showing 1651 to 1675 of 13,155 assets
Previous
Page 67 of 527
Next